Molecular Monitoring in CML and ALL

This information was originally presented on September 20, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the clinical evidence regarding the prognostic significance of early molecular response to TKI therapy and the significance of molecular monitoring in patients with CML
  • Recognize the significance of molecular monitoring in patients with ALL
Additional information
Supporters: 

Supported by educational grants from:

  • Genentech USA, Inc.
  • Janssen Biotech, Inc., administered by Janssen Services, LLC.
  • Jazz Pharmaceuticals, Inc.
  • Millennium: The Takeda Oncology Company
  • Onyx Pharmaceuticals, Inc.
  • Sigma-Tau Pharmaceuticals, Inc.
Course summary
Available credit: 
  • 0.50 Participation
  • 0.60 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician
Course opens: 
11/27/2013
Course expires: 
11/27/2014
Cost:
$0.00

Neil P. Shah, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center  

Available Credit

  • 0.50 Participation
  • 0.60 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician

Accreditation Period

Course opens: 
11/27/2013
Course expires: 
11/27/2014

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing